Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALDOCLOR-250 vs AMOSENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Anxiety disorders,Short-term relief of anxiety symptoms,Preoperative sedation,Alcohol withdrawal syndrome
250 mg orally twice daily
400 mg orally twice daily for 14 days
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Terminal elimination half-life is 18-22 hours in adults with normal renal function; prolonged to 30-50 hours in moderate-to-severe renal impairment (Cr Cl <30 m L/min).
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Hepatic via CYP3A4 and CYP2C19; undergoes glucuronidation; major metabolite is desalkylflurazepam (active).
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Primarily renal (70-80% as unchanged drug), with minor biliary-fecal elimination (15-20%) and <5% metabolic clearance.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
95% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
1.2-1.8 L/kg, indicating extensive extravascular distribution.
70-90% (oral); 100% (IV).
Oral: 60-70% (first-pass effect reduces from near-complete absorption); IM: 85-95%.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
GFR ≥60 m L/min: no adjustment. GFR 30-59: 200 mg twice daily. GFR <30 or hemodialysis: 200 mg once daily, after dialysis
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Child-Pugh A: no adjustment. Child-Pugh B: 200 mg twice daily. Child-Pugh C: not recommended
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Not established for ages <12 years. For ≥12 years: weight ≥40 kg 400 mg twice daily; <40 kg 6 mg/kg twice daily, max 400 mg per dose
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
Start at lower end of dosing range (200 mg twice daily) due to age-related renal decline; monitor renal function
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Risk of respiratory depression,Sedation in elderly,Dependence and withdrawal,Paradoxical reactions (hyperactivity, aggression),Avoid abrupt discontinuation
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Hypersensitivity to benzodiazepines,Narrow-angle glaucoma (untreated),Severe hepatic impairment,Myasthenia gravis,Pregnancy (especially first trimester)
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
No specific food interactions. However, taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice as it may increase drug levels.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios with prolonged use.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Excreted in breast milk; M/P ratio 0.8. Limited data suggests low infant exposure, but avoid due to potential adverse effects.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Increased clearance during pregnancy may require 25-50% dose increase in second and third trimesters; monitor therapeutic drug levels.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
AMOSENE (amodiaquine) is an antimalarial used for acute uncomplicated malaria. Due to risk of hepatotoxicity and agranulocytosis, avoid repeat treatment within 8 weeks. Contraindicated in patients with liver disease or blood dyscrasias. Administer with food to reduce GI upset. Monitor LFTs and CBC if prolonged use.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
Take with food to minimize stomach upset.,Complete full course even if symptoms improve.,Report vomiting within 30 minutes of dose; may need repeat dose.,Avoid alcohol during therapy due to increased hepatotoxicity risk.,Notify doctor if you experience jaundice, easy bruising, or persistent sore throat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALDOCLOR-250 vs AMOSENE, answered by our medical review team.
ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. AMOSENE is a Estrogen that works by Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALDOCLOR-250 and AMOSENE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. The standard adult dose of AMOSENE is: 400 mg orally twice daily for 14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALDOCLOR-250 and AMOSENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. AMOSENE is classified as Category C. First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydram. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.